LDS/Medical Tests/Human Papillomavirus (HPV) 16 and 18/45 Genotype

Human Papillomavirus (HPV) 16 and 18/45 Genotype

Human papilloma virus (HPV) is one of the most common sexually transmitted infections. There are over 50 HPV genotypes that are known to infect the genital tract. Of these, only a small number of subtypes have been linked as a causative source of cervical cancer. These are conventionally recognized as “high-risk” HPV genotypes. Of the 14 recognized high-risk types of HPV, types 16 and 18 are prevalent and are more oncogenic than other high-risk types.

Several studies have demonstrated that cytology-negative women who are positive for HPV16 or 18 are at greater risk of having or developing cervical intraepithelial neoplasia of grade 3 (CIN3, high grade squamous intraepithelial lesion) than women with low-grade squamous intraepithelial lesion (LSIL) cytology without high-risk HPV. In addition, the presence of high-risk HPV DNA in conjunction with an equivocal or ambiguous cytology result (atypical squamous cells of undetermined significance (ASCUS)) is consistent with increased risk of having an underlying cervical intraepithelial neoplasia of grade 2 or 3 (CIN2 or CIN3). CIN3, while occurring in only approximately 5% of ASCUS cases, is an immediate precursor to cervical cancer and consequently its detection is very important for patient management. Therefore, determination of HPV status is a useful adjunct in the evaluation of patients with ASCUS cytology and assists in the risk assessment for more aggressive treatment regimens.

Based on the studies reported in 2006, it was determined that in cytology-negative women 30 years of age and older who are HPV high-risk positive, further clarification of HPV 16/18 genotype status would be clinically useful for triage of patients. Results would help determine treatment course and recommendation for colposcopy versus those who could be followed up with repeat cytology and high-risk HPV testing in 12 months.

  • Monitoring disease progress in infected patients with high risk HPV
  • Evaluation of patients with negative cytology and positive HPV testing
  • Selecting the best available therapy for infected patients
  • Treatment monitoring
  • HPV disease prevention

Positive:

  • Patients with positive HPV and negative PAP smear
  • Patients with positive HPV types 16 and/or 18 and positive PAP (abnormal cytology), who have a higher risk of disease progression and who should be closely monitored

Negative (Not detected)

 

Polymerase chain reaction (PCR), Invader, reverse blot hybridization.

Endocervical specimen collection using the ThinPrep® PapTestTM collection vial. SurePath collection, swabs collected in SMT media, M4 media.

PAP smear (cytology testing), HPV high risk testing, HPV high-risk full genotyping, cervical biopsy, q3 chromosomal abnormality by FISH.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login